Journal of Clinical Oncology, Vol 1, 91-98, Copyright © 1983 by American Society of Clinical Oncology

ARTICLES

Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M- BACOD)

AT Skarin, GP Canellos, DS Rosenthal, DC Case Jr, JM MacIntyre, GS Pinkus, WC Moloney and E Frei 3d

A new combination chemotherapy program (M-BACOD) was administered to 101 patients with advanced diffuse histiocytic and diffuse undifferentiated lymphoma (DHL and DUL). High dose methotrexate (M) 3 g/m2 with leucovorin factor rescue was given on day 14 between cycles of bleomycin (B), adriamycin (A), cyclophosphamide (C), oncovin (O), and dexamethasone (D) administered every 3 weeks for 10 cycles. The complete remission rate (CR) was 72% in all 101 patients or 77% in 95 evaluable patients. The median follow-up is 3 yr 2 mo with one-third of CR patients followed beyond 4 yr. Twenty-six percent of CR patients have relapsed with a projected 5-yr survival rate of 80% (5-yr disease- free rate 65%). The overall survival of all 101 study patients reaches a plateau at 59% projected out to 5 yr. Patients with prior therapy had a significantly lower CR rate than those without prior treatment (p = 0.001); however, no other unfavorable prognostic characteristics could be identified. Relapse in the central nervous system CNS occurred in only 5.4% of CR patients. M-BACOD results in prolonged survival and possible cure in a high proportion of all patients with DHL and DUL.

Related Article

• What Constitutes "Improved Prognosis"?
  George P. Canellos
  JCO 2008 26: 1913-1914 [Full Text]

This article has been cited by other articles:

				G. P. Canellos What Constitutes "Improved Prognosis"? J. Clin. Oncol., April 20, 2008; 26(12): 1913 - 1914. [Full Text] [PDF]

				B. D. Cheson and G. P. Canellos The cancer and leukemia group B lymphoma committee. Clin. Cancer Res., June 1, 2006; 12(11): 3572s - 3575s. [Abstract] [Full Text] [PDF]

				A. M. Levine, L. Seneviratne, B. M. Espina, A. R. Wohl, A. Tulpule, B. N. Nathwani, and P. S. Gill Evolving characteristics of AIDS-related lymphoma Blood, December 15, 2000; 96(13): 4084 - 4090. [Abstract] [Full Text] [PDF]

				L. F. Verdonck, W. L.J. van Putten, A. Hagenbeek, H. C. Schouten, P. Sonneveld, G. W. van Imhoff, H. C. Kluin-Nelemans, J. M.M. Raemaekers, R. H.J. van Oers, H. L. Haak, et al. Comparison of CHOP Chemotherapy with Autologous Bone Marrow Transplantation for Slowly Responding Patients with Aggressive Non-Hodgkin's Lymphoma N. Engl. J. Med., April 20, 1995; 332(16): 1045 - 1051. [Abstract] [Full Text] [PDF]

				R. M. Meyer, I. C. Quirt, J. R. Skillings, M.C. Cripps, V. Bramwell, B. H. Weinerman, M. K. Gospodarowicz, B. F. Burns, A. M. Sargeant, L. E. Shepherd, et al. Escalated as Compared with Standard Doses of Doxorubicin in BACOP Therapy for Patients with Non-Hodgkin's Lymphoma N. Engl. J. Med., December 9, 1993; 329(24): 1770 - 1776. [Abstract] [Full Text]

				R. I. Fisher, E. R. Gaynor, S. Dahlberg, M. M. Oken, T. M. Grogan, E. M. Mize, J. H. Glick, C. A. Coltman, and T. P. Miller Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's Lymphoma N. Engl. J. Med., April 8, 1993; 328(14): 1002 - 1006. [Abstract] [Full Text]

				E. FREI III Cancer Chemotherapy Science, April 15, 1983; 220(4594): 254 - 256. [PDF]